DE19850445A1 - Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen - Google Patents

Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen

Info

Publication number
DE19850445A1
DE19850445A1 DE19850445A DE19850445A DE19850445A1 DE 19850445 A1 DE19850445 A1 DE 19850445A1 DE 19850445 A DE19850445 A DE 19850445A DE 19850445 A DE19850445 A DE 19850445A DE 19850445 A1 DE19850445 A1 DE 19850445A1
Authority
DE
Germany
Prior art keywords
medicament according
drug
core
metronidazole
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19850445A
Other languages
German (de)
English (en)
Inventor
Manfred Kist
Norbert Otterbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Falk Pharma GmbH
Original Assignee
Dr Falk Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma GmbH filed Critical Dr Falk Pharma GmbH
Priority to DE19850445A priority Critical patent/DE19850445A1/de
Priority to PCT/EP1999/008191 priority patent/WO2000025756A2/fr
Publication of DE19850445A1 publication Critical patent/DE19850445A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19850445A 1998-11-02 1998-11-02 Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen Withdrawn DE19850445A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19850445A DE19850445A1 (de) 1998-11-02 1998-11-02 Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
PCT/EP1999/008191 WO2000025756A2 (fr) 1998-11-02 1999-10-28 Medicament pour le traitement topique de maladies intestinales inflammatoires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19850445A DE19850445A1 (de) 1998-11-02 1998-11-02 Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen

Publications (1)

Publication Number Publication Date
DE19850445A1 true DE19850445A1 (de) 2000-05-04

Family

ID=7886406

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19850445A Withdrawn DE19850445A1 (de) 1998-11-02 1998-11-02 Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen

Country Status (2)

Country Link
DE (1) DE19850445A1 (fr)
WO (1) WO2000025756A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
WO2012075015A2 (fr) * 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques orales de métronidazole
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
US20170202818A1 (en) 2014-07-18 2017-07-20 Ohio University Methods and compositions to modify gsk-3 activity
WO2016100203A1 (fr) * 2014-12-20 2016-06-23 Gregg John Malcolm Hall Synthèse de médicament antimicrobien et compositions thérapeutiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020383A1 (fr) * 1994-01-27 1995-08-03 G.D. Searle & Co. Compositions de metronidazole a liberation modifiee et leurs procedes de fabrication et d'utilisation
WO1997002020A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee
WO1998005303A1 (fr) * 1996-08-02 1998-02-12 Farmigea S.P.A. Complexes bioadhesifs de medicaments antifongiques ou antiprotozoaires du type polycarbophil et azole
WO1998011879A1 (fr) * 1996-09-19 1998-03-26 Depomed, Inc. Formes galeniques orales retenues dans l'estomac, pour la liberation controlee de medicaments faiblement solubles et de substance insoluble
WO1998052547A1 (fr) * 1997-05-24 1998-11-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Microspheres de retention gastrique a liberation regulee assurant une meilleure administration de medicaments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135582T1 (de) * 1985-06-13 1996-04-15 Barry James Marshall Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
KR100232297B1 (ko) * 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US7341741B1 (en) * 1997-09-26 2008-03-11 Jean-Pierre Sachetto Pharmaceutical composition for the treatment of inflammatory bowel disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020383A1 (fr) * 1994-01-27 1995-08-03 G.D. Searle & Co. Compositions de metronidazole a liberation modifiee et leurs procedes de fabrication et d'utilisation
WO1997002020A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee
WO1998005303A1 (fr) * 1996-08-02 1998-02-12 Farmigea S.P.A. Complexes bioadhesifs de medicaments antifongiques ou antiprotozoaires du type polycarbophil et azole
WO1998011879A1 (fr) * 1996-09-19 1998-03-26 Depomed, Inc. Formes galeniques orales retenues dans l'estomac, pour la liberation controlee de medicaments faiblement solubles et de substance insoluble
WO1998052547A1 (fr) * 1997-05-24 1998-11-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Microspheres de retention gastrique a liberation regulee assurant une meilleure administration de medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Derwent Abstract, Ref. 98-437043/37 zu WO 9832427 A1 *
PERITI,Piero, et.al.: Current Chemotherapy and Immunotherapy, American Society for Microbiology, Washington, D.C., U.S.A., Vol.1, 1981, S.111-113 *

Also Published As

Publication number Publication date
WO2000025756A2 (fr) 2000-05-11
WO2000025756A3 (fr) 2000-07-27

Similar Documents

Publication Publication Date Title
EP0977557B1 (fr) Formulation de type pellet, s'utilisant dans le traitement du tractus intestinal
DE69720985T2 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
EP0068191B1 (fr) Formes orales du dipyridamole
DE60221691T2 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
EP1439829B1 (fr) Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
DE69628551T2 (de) Oral anzuwendende pharmazeutische dosierungsformen,enthaltend einem protonenpunpeninibitor und einen nicht-steriodalen antiinflamatorischen wirkstoff
EP0934058B1 (fr) Forme stable de medicament pour administration par voie orale, a base de derives de benzimidazole comme principe actif, et son procede de productionn
DE60222687T3 (de) Pharmazeutische zusammensetzungen enthaltend mycophenolsäure oder ein mycophenolat salz
DE60133319T3 (de) Mehrfach beschichete pharmazeutische dosierungsform
EP1113787B1 (fr) Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
DE102004062475A1 (de) Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE602006000819T2 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
EP0682945A2 (fr) Préparation orale à effet retard
EP1017392B1 (fr) Formulation medicamenteuse a liberation controlee du principe actif
DE202006020331U1 (de) Neue, pharmazeutische modifizierte Freisetzungs-Dosisform Cyclooxygenase-Enzym-Inhibitor
CH705273B1 (de) Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
EP0250648A2 (fr) Préparation pharmaceutique pour la libération retardée de l'ibuprofène
EP0994696B1 (fr) Preparations pharmaceutiques a liberation controlee contenant un inhibiteur de l'enzyme de conversion de l'angiotensine comme principe actif
DE102009033621A1 (de) Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
DE10209979A1 (de) Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
EP1315481A1 (fr) Medicament pour le traitement de maladies intestinales
DE19850445A1 (de) Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
EP3162362A1 (fr) Comprimé optimisé a une haute dose contenant de la mesalazine
WO2001068056A1 (fr) Glucocorticoide dans une formulation a liberation modifiee
WO2000048577A1 (fr) Medicament destine au traitement ou a la prevention du cancer de l'intestin

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8139 Disposal/non-payment of the annual fee